Québec: Companies connecting with talent
Québec is a major North American centre for the life sciences industry. Companies will find everything they need to design and test innovative products and technologies—including in tomorrow’s key fields.
- More than 450 companies are engaged in basic research, manufacturing, biotechnology, contract research and medical technology.
- Many world-renowned research centres are gaining international recognition for their major scientific breakthroughs.
- International giants such as Pfizer, Sanofi and Merck have chosen Québec as the site for their Canadian headquarters.
The industry in figures
- More than 450 life-sciences companies employ over 25,400 skilled workers.
- Over 10,000 researchers work in biomedical research centres.
- Each year, 10,000 students graduate from health-related programs.
Fiso Technologies seeks to take on the North American market
A true leader in the development and manufacture of fibre optic sensors and signal conditioners, Fiso Technologies has announced the expansion of its activities in North America. Indeed, with the opening of a cleanroom on Montréal’s South Shore, these new environmentally controlled facilities will allow the company to meet the growing demand from its international customer base.
New facilities in Québec City for Medicago
Medicago< , an international leader in the development and production of plant-based vaccines and therapeutics, has chosen Québec City to house its new production facilities. Medicago uses plants to produce large quantities of vaccines or treatments quickly. It demonstrated its potential for responding to global pandemics by producing candidate vaccines for H1N1 in 2009 and H7N9 in 2013 in just 19 days, compared to the several months required to produce vaccines using eggs.
Creation of an oncology research facility in Montréal
The French biotechnology company Oncodesign has established a joint venture with Mispro Biotech Services to set up a research facility in Montréal. This facility will allow Oncodesign to expand its experimentation operations and respond more effectively to the needs of its North American customers by performing its pre-clinical pharmacology research directly on site. Specialized in the discovery of new therapeutic molecules to fight cancer and other serious illnesses, Oncodesign has also opened a sales and marketing subsidiary near Boston.
Green Cross sets up new plant in Montréal
An acknowledged global leader in the biopharmaceutical industry eager to break into the North American market, the Korean company Green Cross has chosen Montréal as the site of a new blood fractionation plant, primarily attracted by the expertise of Québec’s manpower. The planned facility in Technoparc Montréal’s Saint-Laurent Campus will help create over 200 jobs.
DalCor and the Montréal Heart Institute joins forces
DalCor Pharmaceuticals Canada Inc. and the Montréal Heart Institute have announced that they are jointly working on a phase III international clinical trial that might result in a major breakthrough in cardiovascular personalized medicine. Based on their genetic profile, 5,000 of 30,000 patients screened across 30 countries will be recruited into this study, which, according to DalCor, is estimated to cost $250 million.
enGene partners with Janssen Biotech
In October 2015, enGene entered into an alliance with Janssen Biotech , a subsidiary of the U.S. multinational Johnson & Johnson. Under the agreement, enGene could receive a financial contribution from Janssen to develop and commercialize new therapies for inflammatory bowel disease, as well as milestone payments up to a total of $441 million.
Medtronic expands its research centre
Medtronic is a leading designer and manufacturer of catheters for the treatment of atrial fibrillation. Encouraged by the vigour of Québec’s biomedical sector, the American corporation has announced an expansion of its research centre in the greater Montréal region. It also plans to increase production at its Pointe-Claire plant on the island of Montréal, in order to better meet global demand.